Johnson & Johnson (J&J) reported third-quarter 2026 revenue of USD 25.399 billion, up 5.9%, with nine-month revenue of USD 74.771 billion, up 7.4%, split between innovative medicine at USD 48.567 billion, up 8.8%, and medtech at USD 26.204 billion, up 4.9%.

Oncology led the innovative-medicine segments at USD 21.981 billion, up 18.7%, driven by Darzalex at USD 12.410 billion, up 18.8%, Erleada at USD 2.967 billion, up 13.5%, and Carvykti at USD 1.964 billion, up 47.4%, while Imbruvica continued to fade to USD 1.822 billion, down 14.8% under competitive pressure.

The bispecific franchise is now a clear growth engine. Tecvayli, Talvey and Rybrevant generated USD 2.137 billion over nine months, up 61.2%, with Rybrevant/Lazcluze at USD 866 million, up 67.4%, Talvey at USD 497 million, up 58.3%, and Tecvayli at USD 774 million, up 56.7%.

Immunology is more mixed, as Tremfya rose 69.7% to USD 6.050 billion, while Stelara fell 56.4% to USD 2.112 billion after loss of exclusivity, and Simponi and Remicade declined. Neuroscience added strength with Spravato at USD 1.676 billion, up 40.5%.

J&J lifted its full-year guidance to USD 101.0 billion to 101.4 billion, implying 7.2% to 7.6% growth, showing confidence in offsetting biosimilar erosion.